Shi Yu, Liu Lu, Yang Hui, Chen Xiao, Wang Yan, Zhao Sishu, Jin Huimin, Wu Yujie
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital), Nanjing, China.
Ann Transl Med. 2021 Jul;9(14):1166. doi: 10.21037/atm-21-3199.
Flow cytometry for immunophenotyping is the main method for diagnosing chronic lymphocytic leukemia (CLL). Differential diagnosis between CLL and other B-chronic lymphoproliferative disorders (B-CLPDs) is sometimes difficult. This study aimed to investigate whether cluster of differentiation 35 (CD35) could be a useful marker for the differential diagnosis of CLL and other B-CLPDs.
The CD35 expression on lymphoma cells from 516 B-CLPD patients (347 CLL, 169 other B-CLPDs) was investigated through flow cytometry analysis. Serum C3 and C4 levels in B-CLPD patients were also evaluated.
The results showed that the expression percentage and mean fluorescence intensity of CD35 were reduced in CLL cases compared with other B-CLPD patients. Furthermore, CD35 <17% produced a sensitivity of 81.8% and a specificity of 88.4% for supporting the diagnosis of CLL. Additionally, the addition of CD35 to Matutes score improved the score's discriminative power. The sensitivity of the Matutes score was improved from 81.3% to 88.5%, and the accuracy was improved from 96.6% to 97.6%. Finally, 15.0% and 16.4% of CLL patients had defective serum C3 and C4 levels at diagnosis, respectively.
Evaluating CD35 expression could have potential differential diagnostic value in distinguishing CLL from other B-CLPDs, especially between CLL and mantle cell lymphoma (MCL).
免疫表型分析的流式细胞术是诊断慢性淋巴细胞白血病(CLL)的主要方法。CLL与其他B细胞慢性淋巴细胞增殖性疾病(B-CLPDs)之间的鉴别诊断有时很困难。本研究旨在探讨分化簇35(CD35)是否可作为CLL与其他B-CLPDs鉴别诊断的有用标志物。
通过流式细胞术分析,研究了516例B-CLPD患者(347例CLL,169例其他B-CLPDs)淋巴瘤细胞上CD35的表达情况。还评估了B-CLPD患者的血清C3和C4水平。
结果显示,与其他B-CLPD患者相比,CLL患者中CD35的表达百分比和平均荧光强度降低。此外,CD35<17%对支持CLL诊断的敏感性为81.8%,特异性为88.4%。此外,将CD35添加到Matutes评分中可提高该评分的鉴别能力。Matutes评分的敏感性从81.3%提高到88.5%,准确性从96.6%提高到97.6%。最后,分别有15.0%和16.4%的CLL患者在诊断时血清C3和C4水平存在缺陷。
评估CD35表达在区分CLL与其他B-CLPDs,尤其是CLL与套细胞淋巴瘤(MCL)方面可能具有潜在的鉴别诊断价值。